А-cтрептококковый тонзиллит: вопросы антибактериальной терапии

1. Bisno AL. Acute pharyngitis: etiology and diagnosis. Pediatrics 1996; 97 (Suppl.): 944–9.
2. Wannamaker LW. Perplexity and precision in the diagnosis of streptococcal pharyngitis. Am J Dis Child 1972; 124: 352–8.
3. Pfoh E, Wessels MR, Goldmann D, Lee GM. Burden and economic cost of group A streptococcal pharyngitis. Pediatrics 2008; 121 (2): 229–34.
4. Беляков В.Д. Сюрпризы стрептококковой инфекции. Вестн. РАМН, 1996; 11: 24–8.
5. Kaplan EL. Global assessment of rheumatic fever and rheumatic heart disease at the close of the century. Influences and dynamics of populations and pathogens: a failure to realize prevention? Circulation 1993; 88 (4–1): 1964–72.
6. Pastore S, De Cunto A, Benettoni A et al. The resurgence of rheumatic fever in a developed country area: the role of echocardiography. Rheumatology 2011; 50 (2): 396–400.
7. Vinker S, Zohar E, Hoffman R, Elhayany A. Incidence and clinical manifestations of rheumatic fever: a 6 year community-based survey. Isr Med Assoc J 2010; 12 (2): 78–81.
8. Насонова В.А., Белов Б.С., Страчунский Л.С. и др. Антибактериальная терапия стрептококкового тонзиллита (ангины) и фарингита. Рос. ревматология. 1999; 4: 20–7.
9. Богомильский М.Р. Детская оториноларингология. М.: Гэотар-Медиа, 2006.
10. McIsaac WJ, Goel V, To T, Low DE. The validity of a sore throat score in family practice. CMAJ 2000; 163 (7): 811–5.
11. Jersid T. Penicillin therapy in scarlet fever and complicating otitis. Lancet 1948; 1: 671–3.
12. Rammelkamp CH, Wannamaker LW, Denny FW. The epidemiology and prevention of rheumatic fever. Bull. New York Acad Med 1952; 2 (5): 321–4.
13. Ginsburg CM, McCracken GH Jr, Steinberg JB et al. Treatment of Group A streptococcal pharyngitis in children. Results of a prospective, randomized study of four antimicrobial agents. Clin Pediatr (Phila) 1982; 21 (2): 83–8.
14. Kafetzis DA, Liapi G, Tsolia M et al. Failure to eradicate Group A beta-haemolytic streptococci (GABHS) from the upper respiratory tract after antibiotic treatment. Int J Antimicrob Agents 2004; 23 (1): 67–71.
15. McCarty JM. Comparative efficacy and safety of cefprozil versus penicillin, cefaclor and erythromycin in the treatment of streptococcal pharyngitis and tonsillitis. Eur J Clin Microbiol Infect Dis 1994; 13 (10): 846–50.
16. Holm SE. Reasons for failures in penicillin treatment of streptococcal tonsillitis and possible alternatives. Pediatr Infect Dis J 1994; 13 (1 Suppl. 1): 66–9.
17. Still JG. Treatment of streptococcal pharyngitis in children with five days of azithromycin suspension. Proc. 34th Ann Meeting ICAAC. Orlando (Florida) 1994; Abstr. M67.
18. Roos K, Larsson P. Loracarbef versus phenoxymethylpenicillin in the treatment of recurrent streptococcal pharyngotonsillitis. Scand J Infect Dis 1997; 29 (2): 141–5.
19. Bergman A, Werner R. Failure of children to receive penicillin by mouth. N Engl J Med 1963; 268: 1334–8.
20. Brook I. The role of beta-lactamase producing bacteria and bacterial interference in streptococcal tonsillitis. Int J Antimicrob Agents 2001; 17 (6): 439–42.
21. Brook I, Gober AE. Persistence of group A beta-hemolytic streptococci in toothbrushes and removable orthodontic appliances following treatment of pharyngotonsillitis. Arch Otolaryngol Head Neck Surg 1998; 124 (9): 993–5.
22. Roos K, Holm SE, Grahn-Hakansson E, Lagergren L. Recolonization with selected alpha-streptococci for prophylaxis of recurrent streptococcal pharyngotonsillitis – a randomized placebo-controlled multicentre study. Scand J Infect Dis 1996; 28 (5): 459–62.
23. Shaikh N, Leonard E, Martin JM. Prevalence of streptococcal pharyngitis and streptococcal carriage in children: a meta-analysis. Pediatrics 2010; 126 (3): e557–64.
24. Sela S, Barzilai A. Why do we fail with penicillin in the treatment of group A streptococcus infections? Ann Med 1999; 31: 303–7.
25. Kaplan EL, Chhatwal GS, Rohde M. Reduced ability of penicillin to eradicate ingested group A streptococci from epithelial cells: clinical and path genetic implications. Clin Infect Dis 2006; 43 (11): 1398–406.
26. Gerber MA, Baltimore RS, Eaton CB et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2009; 119 (11): 1541–51.
27. Shulman ST, Bisno AL, Clegg HW et al. Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America. Clin Infect Dis 2012; 9.
28. Lennon DR, Farrell E, Martin DR, Stewart JM. Once-daily amoxicillin versus twice-daily penicillin V in group A beta-haemolytic streptococcal pharyngitis. Arch Dis Child 2008; 93 (6): 474–8.
29. Clegg HW, Ryan AG, Dallas SD et al. Treatment of streptococcal pharyngitis with once-daily compared with twice-daily amoxicillin: a noninferiority trial. Pediatr Infect Dis J 2006; 25 (9): 761–7.
30. Shvartzman P, Tabenkin H, Rosentzwaig A, Dolginov F. Treatment of streptococcal pharyngitis with amoxycillin once a day. BMJ 1993; 306 (6886): 1170–2.
31. Feder HM, Gerber MA, Randolph MF et al. Once-daily therapy for streptococcal pharyngitis with amoxicillin. Pediatrics 1999; 103 (1): 47–51.
32. Regoli M, Chiappini E, Bonsignori F et al. Update on the management of acute pharyngitis in children. Ital J Pediatr 2011; 37: 10.
33. Chiappini E, Regoli M, Bonsignori F et al. Analysis of different recommendations from international guidelines for the management of acute pharyngitis in adults and children. Clin Ther 2011; 33 (1): 48–58.
34. Zavadska D, Bērziņa D, Drukaļska L et al. Macrolide resistance in group A beta haemolytic Streptococcus isolated from outpatient children in Latvia. APMIS 2010; 118 (5): 366–70.
35. Savoia D, Avanzini C, Bosio K et al Macrolide resistance in group A streptococci. J Antimicrob Chemother 2000; 45: 41–7.
36. Silva-Costa C, Ramirez M, Melo-Cristino J. Rapid inversion of the prevalences of macrolide resistance phenotypes paralleled by a diversification of T and emm types among Streptococcus pyogenes in Portugal. Antimicrob Agents Chemother 2005; 49 (5): 2109–11.
37. Bozdogan B, Appelbaum PC, Kelly LM et al. Activity of telithromycin compared with seven other agents against 1039 Streptococcus pyogenes pediatric isolates from ten centers in central and Eastern Europe. Clin Microbiol Infect 2003; 9: 741–5.
38. Alos JI, Aracil B, Oteo J et al. High prevalence of erythromycin-resistant clindamycin/miocamycin-susceptible (M-phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998. J Antimicrob Chemother 2000; 45: 605–9.
39. Grivea IN, Al-Lahham A, Katopodis GD et al. Resistance to erythromycin and telithromycin in Streptococcus pyogenes isolates obtained between 1999 and 2002 from Greek children with tonsillopharyngitis: phenotypic and genotypic analysis. 
Antimicrob Agents Chemother 2006; 50 (1): 256–61.
40. Szszypa K, Sadowy E, Izdebski R et al. A rapid increase in macrolide resistance in Streptococcus pyogenes isolates in Poland during 1996–2002. J Antimicrob Chemother 2004; 54: 828–31.
41. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pyogenes в различных регионах России: результаты многоцентрового проспективного исследования ПеГАС-I. Клин. микробиол. антимикроб. химиотер. 2005; 7 (2): 154–66.
42. Seppala H, Klaukka T, Vuopio-Varkila J et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997; 337 (7): 441–6.
43. Logan LK, McAuley JB, Shulman ST. Macrolide treatment failure in streptococcal pharyngitis resulting in acute rheumatic fever. Pediatrics 2012; 129 (3): e798–802.
44. McCarty J, Hedrick JA, Gooch WM. Clarithromycin suspension vs penicillin V suspension in children with streptococcal pharyngitis. Adv Ther 2000; 17: 14–26.
45. Mehra S, van Moerkerke M, Welck J et al. Short course therapy with cefuroxime axetil for group A streptococcal tonsillopharyngitis in children. Pediatr Infect Dis J 1998; 17: 452–7.
46. Adam D, Hostalek U, Troster K. 5-day therapy of bacterial pharyngitis and tonsillitis with cefixime: comparison with 10-day treatment with penicillin. Klin Padiatr 1996; 208: 310–3.
47. Tack KJ, Hedrick JA, Rothstein E et al. A study of 5-day cefdinir treatment for streptococcal pharyngitis in children. Cefdinir Pediatric Pharyngitis Study Group. Arch Pediatr Adolesc Med 1997; 151 (1): 45–9.
48. Pichichero ME, Gooch WM, Rodriguez W et al. Effective short-course treatment of acute group A beta-hemolytic streptococcal tonsillopharyngitis. Ten days of penicillin V vs 5 days or 10 days of cefpodoxime therapy in children. Arch Pediatr Adolesc Med 1994; 148 (10): 1053–60.
49. McNeil SA, Halperin SA, Langley JM et al. Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005; 41: 1114–22.
50. Casey JR, Pichichero ME. Higher dosages of azithromycin are more effective in treatment of group A streptococcal tonsillopharyngitis. Clin Infect Dis 2005; 40 (12): 1748–55.
51. Altamimi S, Khalil A, Khalaiwi KA et al. Short versus standard duration antibiotic therapy for acute streptococcal pharyngitis in children. Cochrane Database Syst Rev 2009; (1): CD004872.

Б.С.Белов 

ФГБУ Научно-исследовательский институт ревматологии РАМН